Neuropace Stock News

New Jersey, United States,- Verified Market Research has recently published a research report titled, Sacral Nerve Stimulation Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective […]

Northern Trust Corp acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,277 shares of the companys stock, valued at approximately $1,696,000. Northern Trust Corp owned 0.29% of NeuroPace as of its []

NeuroPace, Inc. (NASDAQ:NPCE) Investment analysts at SVB Leerink cut their FY2021 earnings per share estimates for shares of NeuroPace in a research note issued on Wednesday, November 10th. SVB Leerink analyst D. Antalffy now expects that the company will post earnings of $9.67 per share for the year, down from their previous forecast of []

JPMorgan Chase & Co. acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 7,993 shares of the companys stock, valued at approximately $191,000. Several other large investors have also made changes to their positions in NPCE. Bellevue Group []

SVB Leerink reaffirmed their buy rating on shares of NeuroPace (NASDAQ:NPCE) in a research note published on Sunday, AnalystRatings.com reports. SVB Leerink currently has a $30.00 price objective on the stock. SVB Leerink also issued estimates for NeuroPaces FY2021 earnings at $9.67 EPS, Q1 2022 earnings at ($0.35) EPS, Q2 2022 earnings at ($0.37) EPS, []

NeuroPace (NASDAQ:NPCE) had its price objective cut by Wells Fargo & Company from $28.00 to $20.00 in a report released on Thursday, The Fly reports. They currently have an overweight rating on the stock. Other research analysts have also issued reports about the company. Robert W. Baird began coverage on NeuroPace in a research report []

NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2021 Results - Earnings Call Transcript

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.

NeuroPace's (NPCE) CEO Mike Favet on Q1 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, t

MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of p